The University of Queensland and CSL are developing a vaccine for Coronavirus (COVID-19). If the vaccine is proven to be safe and effective, and is approved for use, it will be available in Australia as part of the Australian Government’s COVID-19 Vaccine and Treatment Strategy.

The Australian Government has provided $5 million to support the development of molecular clamp technology for this vaccine. It is also funded by the Queensland Government, the international Coalition for Epidemic Preparedness Innovation (CEPI), CSL and philanthropic organisations.

The vaccine doses purchased by the Australian Government will be manufactured in Australia at CSL’s biologics facility in Broadmeadows Victoria. The vaccine is one of nine vaccines supported by CEPI, a global partnership to accelerate vaccine development.

<table>
<thead>
<tr>
<th>Status</th>
<th>Type</th>
<th>Developer</th>
<th>Likely doses*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase 1 clinical trials</td>
<td>Protein vaccine</td>
<td>CSL</td>
<td>Two</td>
</tr>
</tbody>
</table>

*Based on early trial results

**Testing Process**

All vaccines must pass different stages of research trials to prove they are safe and effective.

The University of Queensland announced that pre-clinical research on their vaccine showed it produced a potent protective immune response. These findings will be submitted to a research journal for peer review.

CSIRO and CSL have developed a process to scale-up, produce and purify the vaccine for Phase 1 clinical trials.

Phase 1 clinical trials in humans began in July 2020 in Brisbane. It is currently being tested in 120 volunteers to show that the vaccine is safe. If this trial is successful, CSL will work with the University of Queensland on a large-scale combined Phase 2b and 3 clinical trial. This is expected to begin in late 2020.

**Doses for Australia**

Before the University of Queensland COVID-19 vaccine is approved for use in Australia it must pass the Therapeutic Goods Administration’s (TGA) rigorous assessment and approval processes. This includes assessment of its safety, quality and effectiveness. The TGA is actively monitoring COVID-19 vaccine development that is occurring both in Australia and around the world.

If the University of Queensland vaccine is successful:

- 51 million doses will be available from mid-2021
- These doses will be manufactured in Australia by CSL